These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19021141)

  • 1. Allosteric regulation of proteases.
    Hauske P; Ottmann C; Meltzer M; Ehrmann M; Kaiser M
    Chembiochem; 2008 Dec; 9(18):2920-8. PubMed ID: 19021141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities for structure-based design of protease-directed drugs.
    Mittl PR; Grütter MG
    Curr Opin Struct Biol; 2006 Dec; 16(6):769-75. PubMed ID: 17112720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of HslUV complexed with a vinyl sulfone inhibitor: corroboration of a proposed mechanism of allosteric activation of HslV by HslU.
    Sousa MC; Kessler BM; Overkleeft HS; McKay DB
    J Mol Biol; 2002 May; 318(3):779-85. PubMed ID: 12054822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
    Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
    J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and structural characterization of Spl proteases from Staphylococcus aureus.
    Popowicz GM; Dubin G; Stec-Niemczyk J; Czarny A; Dubin A; Potempa J; Holak TA
    J Mol Biol; 2006 Apr; 358(1):270-9. PubMed ID: 16516230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design.
    Tully DC; Vidal A; Chatterjee AK; Williams JA; Roberts MJ; Petrassi HM; Spraggon G; Bursulaya B; Pacoma R; Shipway A; Schumacher AM; Danahay H; Harris JL
    Bioorg Med Chem Lett; 2008 Nov; 18(22):5895-9. PubMed ID: 18752942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteases universally recognize beta strands in their active sites.
    Tyndall JD; Nall T; Fairlie DP
    Chem Rev; 2005 Mar; 105(3):973-99. PubMed ID: 15755082
    [No Abstract]   [Full Text] [Related]  

  • 8. Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites.
    Othman R; Kiat TS; Khalid N; Yusof R; Newhouse EI; Newhouse JS; Alam M; Rahman NA
    J Chem Inf Model; 2008 Aug; 48(8):1582-91. PubMed ID: 18656912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric antibody inhibition of human hepsin protease.
    Koschubs T; Dengl S; Dürr H; Kaluza K; Georges G; Hartl C; Jennewein S; Lanzendörfer M; Auer J; Stern A; Huang KS; Packman K; Gubler U; Kostrewa D; Ries S; Hansen S; Kohnert U; Cramer P; Mundigl O
    Biochem J; 2012 Mar; 442(3):483-94. PubMed ID: 22132769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8.
    James KE; Asgian JL; Li ZZ; Ekici OD; Rubin JR; Mikolajczyk J; Salvesen GS; Powers JC
    J Med Chem; 2004 Mar; 47(6):1553-74. PubMed ID: 14998341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the means to the end in ATP-dependent proteases.
    Hochstrasser M; Wang J
    Nat Struct Biol; 2001 Apr; 8(4):294-6. PubMed ID: 11276243
    [No Abstract]   [Full Text] [Related]  

  • 12. Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.
    Shiraishi T; Kadono S; Haramura M; Kodama H; Ono Y; Iikura H; Esaki T; Koga T; Hattori K; Watanabe Y; Sakamoto A; Yoshihashi K; Kitazawa T; Esaki K; Ohta M; Sato H; Kozono T
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4533-7. PubMed ID: 18674905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural occurring polyphenols as template for drug design. Focus on serine proteases.
    Cuccioloni M; Mozzicafreddo M; Bonfili L; Cecarini V; Eleuteri AM; Angeletti M
    Chem Biol Drug Des; 2009 Jul; 74(1):1-15. PubMed ID: 19519739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversity of allosteric regulation in proteases.
    Merdanovic M; Mönig T; Ehrmann M; Kaiser M
    ACS Chem Biol; 2013 Jan; 8(1):19-26. PubMed ID: 23181429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural basis of allosteric regulation in proteins.
    Laskowski RA; Gerick F; Thornton JM
    FEBS Lett; 2009 Jun; 583(11):1692-8. PubMed ID: 19303011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of caspases.
    Häcker HG; Sisay MT; Gütschow M
    Pharmacol Ther; 2011 Nov; 132(2):180-95. PubMed ID: 21807025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding.
    Szeltner Z; Rea D; Juhász T; Renner V; Fülöp V; Polgár L
    J Mol Biol; 2004 Jul; 340(3):627-37. PubMed ID: 15210359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many faces of protease-protein inhibitor interaction.
    Otlewski J; Jelen F; Zakrzewska M; Oleksy A
    EMBO J; 2005 Apr; 24(7):1303-10. PubMed ID: 15775973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric regulation and catalysis emerge via a common route.
    Goodey NM; Benkovic SJ
    Nat Chem Biol; 2008 Aug; 4(8):474-82. PubMed ID: 18641628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.